6CM
SPRB

683 Capital Management’s Spruce Biosciences SPRB Stock Holding History

683 Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,879
Closed -$73K – 156
2024
Q2 		$73K Buy
+1,879
New +$101K 0.01% 116

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

683 Capital Management's SPRB Position: Q3 2024 in Review

683 Capital Management sold out of Spruce Biosciences (SPRB) in Q3 2024, closing a stake of 1,879 shares — an estimated $73K sold.

683 Capital Management first reported a position in SPRB in Q2 2024 and held it in 1 quarter. The position peaked at $73K in Q2 2024. 29 funds tracked by Wall St. Rank hold SPRB as of Q3 2024.

  • 683 Capital Management reported no remaining Spruce Biosciences position as of Q3 2024 after selling out during the quarter.
  • 683 Capital Management sold 1,879 Spruce Biosciences shares in Q3 2024, an estimated $73K.
  • 683 Capital Management first reported a position in Spruce Biosciences in Q2 2024 and held it in 1 quarter.
  • 683 Capital Management's Spruce Biosciences position peaked at $73K in Q2 2024.
  • 29 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2024.

Based on 683 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.